Takeaways: By combining a TSXV listing with a Health Canada-accepted ANDS for a domestically made generic Ozempic, Vimy is positioning itself to compete in a fast-growing, high-value GLP-1 marke...
Takeaways: SteriMax’s acquisition of Andone broadens its growth runway beyond injectables into two adjacent, higher-diversification markets, medical devices and veterinary, so the main mark...
Takeaways: Vimy Pharma’s filing could position it as a domestic, lower-cost semaglutide supplier in Canada, which supports affordability and national supply resilience. The broader market ...
The pharmaceutical industry has historically operated as one of the world’s most globally interconnected sectors, relying on international supply chains, cross border research collaboration, and multi...
Takeaways: Dr. Reddy’s has become the first company to secure Health Canada approval for a generic semaglutide injection (Ozempic equivalent), with an NOC covering 2 mg and 4 mg once‑weekly pens...
Contract development and manufacturing organizations, often referred to as CDMOs, were once viewed primarily as outsourced service providers supporting pharmaceutical production. Today, their role is ...
Cell and gene therapies are redefining the future of medicine, offering the possibility of long term remission and even cures for diseases once considered untreatable. Yet despite this scientific prom...
